AZN logo

AZN AstraZeneca PLC

New York Stock Exchange · Drug Manufacturers - General · Healthcare

$174.35
-1.06 (-0.60%)

AstraZeneca PLC operates as a biopharmaceutical company, specializing in the discovery, development, manufacturing, and commercialization of prescription medications. Its comprehensive portfolio addresses diverse therapeutic areas. In oncology, key marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex. For cardiovascu…

Market Cap: $270.39Bwww.astrazeneca.com

Price

$186.65+10.01%
$155.82$166.10$176.37$186.65
Aug 25Oct 30

Social Signal Score

38
5d
30
1 mentions
+0.0%
30d
43
24 mentions
+8.8%
60d
41
61 mentions
+14.3%
90d
40
94 mentions
+12.0%
news: 94

Analyst Ratings

41 analysts
Buyconsensus
Strong Buy 1Buy 19Hold 15Sell 6Strong Sell 0
Avg price target$211+21.0%
Low $206Median $211High $216
Current Consensus

52-week range

$155.62$209.48
Last close
$186.65
Off 52w high
-10.9%
200-day average
$180.04
vs 200-day
+3.7%

Revenue

$15.99B+186.36%
$5.05B$8.70B$12.35B$15.99B
Dec 2016Sep 2026

Analyst Estimates

FY2025
$9.16
$8.83–$9.42
4 analysts
FY2026
$10.26+12% YoY
$10.09–$10.36
7 analysts
FY2027
$11.37+11% YoY
$11.12–$11.83
8 analysts

Consensus estimates, not results. Via Financial Modeling Prep.

Company Profile

CEO
Pascal Claude Roland Soriot
Sector
Healthcare
Industry
Drug Manufacturers - General
Employees
96,100
Beta
0.21
Country
GB
Piotroski score
7 / 9 (Strong)
Altman Z-score
3.48
www.astrazeneca.com